Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

It might be that there are those who will disagree with the various p/s variations you offer, but they make a salient point about both Elite and big pharma on a buyout. Once the proof of concept is established, the discussion of a projected market capture will be on the table as THE SINGLE MOST IMPORTANT ASPECT FOR A BUYOUT PRICE (well, beyond negotiating ability - but that is why Elite has its robustly credited BOD). What will NOT be part of the discussion will be p/s, as it is a byproduct of the buyout price. Most assuredly, the projections of the anticipated percentage of market share capture will drive the negotiations. And, that is why I continue to argue the time to leverage the most value inducing buyout price for shareholders is upon FDA approval that confers proof of concept.

AND...To the point of an acquisition, there is absolutely NO VALUE in uplisting to the Nasdaq. That takes time and money not well spent. If anyone is unclear on that point, do some DD. Thinking that uplisting somehow makes Elite more attractive to a buyer fails miserably the test of reality. Neither where a firm is listed nor its p/s has a material impact on the price an acquirer is willing to pay. It is all about the future value that can be derived from the product/s.